Dr. Mehdi Farokhnia received his medical degree from Tehran University of Medical Sciences in 2012 and joined the CPN laboratory in May 2014. His research has been focused on investigating the neurobiological mechanism underlying psychiatric disorders to identify novel neuropsychopharmacological targets. As a Post-Doctoral Fellow in Dr. Leggio’s laboratory, Dr. Farokhnia has conducted several projects including two major clinical protocols (13-AA-0040 and 13-AA-0043) as Lead Associate Investigator. Dr. Farokhnia is also interested in investigating innovative methodological approaches that may best translate preclinical findings into human research, with a particular focus on behavioral pharmacology and substance use. Dr. Farokhnia has been the recipient of several awards from Society of Biological Psychiatry, American Society of Clinical Psychopharmacology, Society for Neuroscience, International Society for CNS Clinical Trials and Methodology, Research Society on Alcoholism, International Society of Addiction Medicine and College on Problems of Drug Dependence. He also received a Fellows Award for Research Excellence (FARE) from the National Institutes of Health (NIH). In 2018, Dr. Farokhnia was awarded with a fellowship from the NIH Center on Compulsive Behaviors to study the neurobiological correlates and pharmacotherapeutic implications of glucagon-like peptide-1 (GLP-1) in compulsive alcohol use. In 2019, Dr. Farokhnia was awarded a William G. Coleman Jr., Ph.D., Minority Health and Health Disparities Research Innovation Award from the National Institute on Minority Health and Health Disparities (NIMHD) and a Pathways Research Award funded by the Alkermes Pathways Research Awards Program.